Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 2, 2008, Pages 265-270

  Kchour, Ghada ^a   Tarhini, Mahdi ^b   Sharifi, Nourieh ^b   Farid, Reza ^a   Khooei, Ali Reza ^b   Shirdel, Abbas ^b   Afshari, Jalil Tavakkol ^a   Sadeghian, Ali ^b   Otrock, Zaher ^c   Hermine, Olivier ^d   El Sabban, Marwan ^c   Bazarbachi, Ali ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Angiogenesis; ATLL; HTLV I; Microvessel density; VEGF

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN; ZIDOVUDINE;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW; CLINICAL ARTICLE; COLON; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN TISSUE; LYMPH NODE; MALE; MICROVASCULATURE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T CELL LEUKEMIA; T CELL LYMPHOMA; VASCULAR ENDOTHELIUM; VIRUS INFECTION; VIRUS LOAD;

ADULT; AGED; BONE MARROW; CAPILLARIES; CASE-CONTROL STUDIES; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPH NODES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SKIN; TESTIS;

EID: 38849173008     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701760060     Document Type: Article

References (30)

1. Takatsuki, F., Yamaguchi, K. and Hattori, T. (1990) Adult T-cell leukemia/lymphoma. Retrovirus Biology and Human Disease, pp. 147-159. Marcel Dekker, New York
2. Hinuma, Y., Komoda, H., Chosa, T., Kondo, T., Kohakura, M. and Takenaka, T. (1982) Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: A nationwide sero-epidemiologic study. Int J Cancer, 29, pp. 631-635.
3. Gessain, A., Barin, F., Vernant, J. C., Gout, O., Maurs, L. and Calender, A. (1985) Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet, 2, pp. 407-410.
4. Kaplan, J. E. and Khabbaz, R. F. (1993) The epidemiology of human T-lymphotropic virus type I and II. Med Virol, 3, pp. 137-148.
5. Gessain, A. (1996) Epidemiology of HTLV-I and associated diseases. Human T-Cell Lymphotropic Virus Type 1, pp. 33-64. John Wiley, New York
6. Safai, B., Huang, J. L., Boeri, E., Farid, R., Raafat, J. and Schutzer, P. (1996) Prevalence of HTLV type I infection in Iran: A serological and genetic study. AIDS Res Hum Retroviruses, 12, pp. 1185-1190.
7. Abbaszadegan, M. R., Gholamin, M., Tabatabaee, A., Farid, R., Houshmand, M. and Abbaszadegan, M. (2003) Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad, Iran. J Clin Microbiol, 41, pp. 2593-2595.
8. Folkman, J. (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med, 285, pp. 1182-1186.
9. Gimbrone, M., Leapman, S., Cotran, R. and Folkman, J. (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med, 136, pp. 261-276.
10. Folkman, J., Watson, K., Ingber, D. and Hanahan, D. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 339, pp. 58-61.
11. Friesel, R. E. and Maciag, T. (1995) Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J, 9, pp. 919-925.
12. Otrock, Z. K., Makarem, J. A. and Shamseddine, A. I. (2007) Vascular endothelial growth factor family of ligands and receptors: Review. Blood Cells Mol Dis, 38, pp. 258-268.
13. El-Sabban, M. E., Merhi, R. A., Haidar, H. A., Arnulf, B., Khoury, H. and Basbous, J. (2002) Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood, 99, pp. 3383-3389.
14. Bazarbachi, A., Merhi, R Abou, Gessain, A., Talhouk, R., El-Khoury, H. and Nasr, R. (2004) Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Cancer Res, 64, pp. 2039-2046.
15. Kchour, G., Makhoul, N. J., Mahmoudi, M., Kooshyar, M. M., Shirdel, A. and Rastin, M. (2007) Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma, 48, pp. 330-336.
16. Shimoyama, M. (1991) Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol, 79, pp. 428-437.
17. Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G. and Silvestris, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol, 87, pp. 503-508.
18. Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M. and Ria, R. (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93, pp. 3064-3073.
19. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P. and Eddlemon, P. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341, pp. 1565-1571.
20. Ribatti, D., Vacca, A., Nico, B., Fanelli, M., Roncali, L. and Dammacco, F. (1996) Angiogenesis spectrum in the stroma of B-cell non Hodgkin's lymphomas: An immunohistochemical and structural study. Eur J Haematol, 56, pp. 45-53.
21. Salven, P., Teerenhovi, L. and Joensuu, H. (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood, 94, pp. 3334-3339.
22. Salven, P., Orpana, A., Teerenhovi, L. and Joensuu, H. (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood, 96, pp. 3712-3718.
23. Ganjoo, K. N., An, C. S., Robertson, M. J., Gordon, L. I., Sen, J. A. and Weisenbach, J. (2006) Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma, 47, pp. 998-1005.
24. Perez-Atayde, A. R., Sallan, S. E., Tedrow, U., Connors, S., Allred, E. and Folkman, J. (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol, 150, pp. 815-821.
25. Padro, T., Ruiz, S., Bieker, R., Burger, H., Steins, M. and Kienast, J. (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, 95, pp. 2637-2644.
26. Hussong, J. W., Rodgers, G. M. and Shami, P. J. (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 95, pp. 309-313.
27. Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E. and Thomas, D. (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 96, pp. 2240-2245.
28. Chen, H., Treweeke, A. T., West, D. C., Till, K. J., Cawley, J. C. and Zuzel, M. (2000) In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood, 96, pp. 3181-3187.
29. Kini, A. R., Kay, N. E. and Peterson, L. C. (2000) Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia, 14, pp. 1414-1418.
30. Zahiragic, L., Schliemann, C., Bieker, R., Thoennissen, N. H., Burow, K. and Kramer, C. (2007) Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia, 21, pp. 1310-1312.